Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology DOI Creative Commons
Alexandra Bartolomucci, Monyse de Nóbrega,

Tadhg Ferrier

et al.

npj Precision Oncology, Journal Year: 2025, Volume and Issue: 9(1)

Published: March 24, 2025

Circulating tumor DNA (ctDNA) has emerged as a dynamic biomarker in cancer, evidenced by its increasing integration into clinical practice. Carrying specific characteristics, ctDNA can be used to inform treatment selection, monitor response, and identify drug resistance. In this review, we provide comprehensive, up-to-date summary of monitoring response with focus on lung, colorectal, breast cancers, discuss current challenges future directions.

Language: Английский

Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology DOI Creative Commons
Alexandra Bartolomucci, Monyse de Nóbrega,

Tadhg Ferrier

et al.

npj Precision Oncology, Journal Year: 2025, Volume and Issue: 9(1)

Published: March 24, 2025

Circulating tumor DNA (ctDNA) has emerged as a dynamic biomarker in cancer, evidenced by its increasing integration into clinical practice. Carrying specific characteristics, ctDNA can be used to inform treatment selection, monitor response, and identify drug resistance. In this review, we provide comprehensive, up-to-date summary of monitoring response with focus on lung, colorectal, breast cancers, discuss current challenges future directions.

Language: Английский

Citations

0